News and events

Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland

Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!

March 27, 2023

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus ...

March 13, 2023

ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank

xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing ...

January 9, 2023

Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA

ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit ...

January 5, 2023

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors. Dr. Bolger has over 35 years ...

October 20, 2022